Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M1069 in advanced solid tumors
NCT05198349Phase 1Terminated
- Sponsor
- EMD Serono
- Start
- Mar 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of M1069 in solid tumor, sponsored by EMD Serono. Primary endpoints: Number of Participants With Dose-Limiting Toxicities at 21 days and Number of Participants With Treatment-emergent Adverse Events, Treatment Related TEAEs and Serious TEAEs up to 16 months. Started Mar 2022; status: terminated.
02
Drugs
M1069
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05198349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05198349.